Fosun-funded Hygtia Therapeutics licenses Insilico’s NLRP3 inhibitor for Parkinson’snews2026-01-21T12:14:26+00:00January 21st, 2026|Endpoints News|
GSK makes $2.2B deal for RAPT and its food allergy candidatenews2026-01-20T10:34:11+00:00January 20th, 2026|Endpoints News|
Makary talks FDA’s plans to combat China’s biotech growthnews2026-01-16T19:51:37+00:00January 16th, 2026|Endpoints News|
#JPM26: Inside Fosun Pharma’s ambition to reach outside of Chinanews2026-01-15T16:31:32+00:00January 15th, 2026|Endpoints News|
#JPM26: Drugmakers want US reforms, not to slow down Chinanews2026-01-14T16:10:57+00:00January 14th, 2026|Endpoints News|
Caldera Therapeutics erupts with $112.5M and a China-originated IBD bispecificnews2026-01-14T12:00:39+00:00January 14th, 2026|Endpoints News|
Novartis licenses radiopharma asset from Chinese biotech for $50M upfrontnews2026-01-13T12:07:22+00:00January 13th, 2026|Endpoints News|
AirNexis gets $200M to test China-derived COPD drugnews2026-01-09T13:00:40+00:00January 9th, 2026|Endpoints News|
Sanofi doubles down on Earendil in $160M near-term dealnews2026-01-05T15:03:58+00:00January 5th, 2026|Endpoints News|
‘Chinese Peptides’ Are the Latest Biohacking Trend in the Tech Worldnews2026-01-03T05:00:14+00:00January 3rd, 2026|The New York Times|
